Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson's disease.

Jillian H Kluss Patrick A Lewis Greggio Elisa

Published in: Expert opinion on therapeutic targets (2022)

The growth of both target discovery and innovative drug design has sparked a lot of excitement for the future of how we treat Parkinson's disease. Given the immense focus on LRRK2 as a therapeutic target, it is expected within the next decade to determine its therapeutic properties, or lack thereof, for PD.

Keyphrases

small molecule
high throughput
current status
tyrosine kinase
protein kinase
risk assessment
drug induced
single cell